Insulin Biologics and Biosimilars - Global and China Top Players Market Share and Ranking 2023
- Report Code : AMP2757523
- Published On: Oct, 2024
- Category : Healthcare & Pharma
- Pages : 135
-
According to Ample Market Research, the global market for Insulin Biologics and Biosimilars should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China Insulin Biologics and Biosimilars market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029. The United States Insulin Biologics and Biosimilars market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By segment, Hospital grew percent to account for percent of the total market sales, and Retail Pharmacy grew percent.
Insulin is a hormone created by your pancreas that controls the amount of glucose in your bloodstream at any given moment. It also helps store glucose in your liver, fat, and muscles. Finally, it regulates your body’s metabolism of carbohydrates, fats, and proteins.
This report studies and analyses global Insulin Biologics and Biosimilars status and future trends, to help determine the Insulin Biologics and Biosimilars market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Insulin Biologics and Biosimilars, and provides market size (US$ million) and Year-over-Year growth, considering 2022 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global Insulin Biologics and Biosimilars market size, history data 2018-2023, and forecast data 2024-2029, (US$ million)
(2) Global Insulin Biologics and Biosimilars by company, revenue, market share and industry ranking 2018-2023, (US$ million)
(3) China Insulin Biologics and Biosimilars by company, revenue, market share and industry ranking 2018-2023, (US$ million)
(4) Global Insulin Biologics and Biosimilars key consuming regions, consumption value and demand structure
(5) Insulin Biologics and Biosimilars industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Novo Nordisk
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Market segment by Type, covers
Insulin Biologics
Insulin Biosimilars
Market segment by Application, can be divided into
Hospital
Retail Pharmacy
Other
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Insulin Biologics and Biosimilars product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Insulin Biologics and Biosimilars market share and ranking of major manufacturers, revenue, 2018-2023
Chapter 3: China Insulin Biologics and Biosimilars market share and ranking of major manufacturers, revenue, 2018-2023
Chapter 4: Insulin Biologics and Biosimilars industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2018-2029
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2018-2029
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2018-2029
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2018-2029
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions
-
With tables and figures helping analyze worldwide Insulin Biologics and Biosimilars Global and China Top Players market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
1 Market Overview1.1 Insulin Biologics and Biosimilars Definition
1.2 Global Insulin Biologics and Biosimilars Market Size and Forecast
1.3 China Insulin Biologics and Biosimilars Market Size and Forecast
1.4 China Percentage in Global Market
1.5 Insulin Biologics and Biosimilars Market Size: China VS Global Growth Rate, 2018-2029
1.6 Insulin Biologics and Biosimilars Market Dynamics
1.6.1 Insulin Biologics and Biosimilars Market Drivers
1.6.2 Insulin Biologics and Biosimilars Market Restraints
1.6.3 Insulin Biologics and Biosimilars Industry Trends
1.6.4 Insulin Biologics and Biosimilars Industry Policy
2 Global Leading Players and Market Share2.1 By Revenue of Insulin Biologics and Biosimilars, Global Market Share by Company, 2018-2023
2.2 Global Insulin Biologics and Biosimilars Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Insulin Biologics and Biosimilars Concentration Ratio
2.4 Global Insulin Biologics and Biosimilars Mergers & Acquisitions, Expansion Plans
2.5 Global Insulin Biologics and Biosimilars Major Companies Product Type
2.6 Head Office and Insulin Biologics and Biosimilars Production Site of Key Manufacturer
3 China Leading Players, Market Share and Ranking3.1 By Revenue of Insulin Biologics and Biosimilars, China Market Share by Company, 2018-2023
3.2 China Insulin Biologics and Biosimilars Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Industry Chain Analysis4.1 Insulin Biologics and Biosimilars Industry Chain
4.2 Insulin Biologics and Biosimilars Upstream Analysis
4.2.1 Insulin Biologics and Biosimilars Core Raw Materials
4.2.2 Main Manufacturers of Insulin Biologics and Biosimilars Core Raw Materials4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Insulin Biologics and Biosimilars Production Mode
4.6 Insulin Biologics and Biosimilars Procurement Model
4.7 Insulin Biologics and Biosimilars Industry Sales Model and Sales Channels
4.7.1 Insulin Biologics and Biosimilars Sales Model
4.7.2 Insulin Biologics and Biosimilars Typical Distributors
5 Sights by Type5.1 Insulin Biologics and Biosimilars Classification
5.1.1 Insulin Biologics
5.1.2 Insulin Biosimilars5.2 By Type, Global Insulin Biologics and Biosimilars Consumption Value & CAGR, 2018 VS 2022 VS 2029
5.3 By Type, Global Insulin Biologics and Biosimilars Consumption Value, 2018-2029
6 Sights by Application6.1 Insulin Biologics and Biosimilars Segment by Application
6.1.1 Hospital
6.1.2 Retail Pharmacy
6.1.3 Other6.2 By Application, Global Insulin Biologics and Biosimilars Consumption Value & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Insulin Biologics and Biosimilars Consumption Value, 2018-2029
7 Sales Sights by Region7.1 By Region, Global Insulin Biologics and Biosimilars Consumption Value, 2018 VS 2022 VS 2029
7.2 By Region, Global Insulin Biologics and Biosimilars Consumption Value, 2018-2029
7.3 North America
7.3.1 North America Insulin Biologics and Biosimilars & Forecasts, 2018-2029
7.3.2 By Country, North America Insulin Biologics and Biosimilars Market Size Market Share7.4 Europe
7.4.1 Europe Insulin Biologics and Biosimilars Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Insulin Biologics and Biosimilars Market Size Market Share7.5 Asia Pacific
7.5.1 Asia Pacific Insulin Biologics and Biosimilars Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Insulin Biologics and Biosimilars Market Size Market Share7.6 South America
7.6.1 South America Insulin Biologics and Biosimilars Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Insulin Biologics and Biosimilars Market Size Market Share
7.7 Middle East & Africa
8 Sales Sights by Country Level8.1 By Country, Global Insulin Biologics and Biosimilars Market Size & CAGR, 2018 VS 2022 VS 2029
8.2 By Country, Global Insulin Biologics and Biosimilars Consumption Value, 2018-2029
8.3 U.S.
8.3.1 U.S. Insulin Biologics and Biosimilars Market Size, 2018-2029
8.3.2 By Type, U.S. Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.3.3 By Application, U.S. Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 20298.4 Europe
8.4.1 Europe Insulin Biologics and Biosimilars Market Size, 2018-2029
8.4.2 By Type, Europe Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.4.3 By Application, Europe Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 20298.5 China
8.5.1 China Insulin Biologics and Biosimilars Market Size, 2018-2029
8.5.2 By Type, China Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.5.3 By Application, China Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 20298.6 Japan
8.6.1 Japan Insulin Biologics and Biosimilars Market Size, 2018-2029
8.6.2 By Type, Japan Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.6.3 By Application, Japan Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Insulin Biologics and Biosimilars Market Size, 2018-2029
8.7.2 By Type, South Korea Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.7.3 By Application, South Korea Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Insulin Biologics and Biosimilars Market Size, 2018-2029
8.8.2 By Type, Southeast Asia Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.8.3 By Application, Southeast Asia Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.9 India
8.9.1 India Insulin Biologics and Biosimilars Market Size, 2018-2029
8.9.2 By Type, India Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.9.3 By Application, India Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 20298.10 Middle East & Africa
8.10.1 Middle East & Africa Insulin Biologics and Biosimilars Market Size, 2018-2029
8.10.2 By Type, Middle East & Africa Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
8.10.3 By Application, Middle East & Africa Insulin Biologics and Biosimilars Consumption Value Market Share, 2022 VS 2029
9 Company Profile9.1 Novo Nordisk
9.1.1 Novo Nordisk Company Information, Head Office, Market Area and Industry Position
9.1.2 Novo Nordisk Company Profile and Main Business
9.1.3 Novo Nordisk Insulin Biologics and Biosimilars Models, Specifications and Application
9.1.4 Novo Nordisk Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.1.5 Novo Nordisk Recent Developments9.2 Eli Lilly
9.2.1 Eli Lilly Company Information, Head Office, Market Area and Industry Position
9.2.2 Eli Lilly Company Profile and Main Business
9.2.3 Eli Lilly Insulin Biologics and Biosimilars Models, Specifications and Application
9.2.4 Eli Lilly Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.2.5 Eli Lilly Recent Developments9.3 Sanofi
9.3.1 Sanofi Company Information, Head Office, Market Area and Industry Position
9.3.2 Sanofi Company Profile and Main Business
9.3.3 Sanofi Insulin Biologics and Biosimilars Models, Specifications and Application
9.3.4 Sanofi Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.3.5 Sanofi Recent Developments9.4 Gan&Lee
9.4.1 Gan&Lee Company Information, Head Office, Market Area and Industry Position
9.4.2 Gan&Lee Company Profile and Main Business
9.4.3 Gan&Lee Insulin Biologics and Biosimilars Models, Specifications and Application
9.4.4 Gan&Lee Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.4.5 Gan&Lee Recent Developments9.5 Tonghua Dongbao
9.5.1 Tonghua Dongbao Company Information, Head Office, Market Area and Industry Position
9.5.2 Tonghua Dongbao Company Profile and Main Business
9.5.3 Tonghua Dongbao Insulin Biologics and Biosimilars Models, Specifications and Application
9.5.4 Tonghua Dongbao Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.5.5 Tonghua Dongbao Recent Developments9.6 United Laboratory
9.6.1 United Laboratory Company Information, Head Office, Market Area and Industry Position
9.6.2 United Laboratory Company Profile and Main Business
9.6.3 United Laboratory Insulin Biologics and Biosimilars Models, Specifications and Application
9.6.4 United Laboratory Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.6.5 United Laboratory Recent Developments
9.7 Geropharm
9.7.1 Geropharm Company Information, Head Office, Market Area and Industry Position
9.7.2 Geropharm Company Profile and Main Business
9.7.3 Geropharm Insulin Biologics and Biosimilars Models, Specifications and Application
9.7.4 Geropharm Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.7.5 Geropharm Recent Developments
9.8 Biocon
9.8.1 Biocon Company Information, Head Office, Market Area and Industry Position
9.8.2 Biocon Company Profile and Main Business
9.8.3 Biocon Insulin Biologics and Biosimilars Models, Specifications and Application
9.8.4 Biocon Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.8.5 Biocon Recent Developments
9.9 Wockhardt
9.9.1 Wockhardt Company Information, Head Office, Market Area and Industry Position
9.9.2 Wockhardt Company Profile and Main Business
9.9.3 Wockhardt Insulin Biologics and Biosimilars Models, Specifications and Application
9.9.4 Wockhardt Insulin Biologics and Biosimilars Revenue and Gross Margin, 2018-2023
9.9.5 Wockhardt Recent Developments
10 Conclusion
11 Appendix11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources11.3 Market Estimation Model
11.4 Disclaimer
-
The Insulin Biologics and Biosimilars Global and China Top Players Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
Recognize the areas along the Insulin Biologics and Biosimilars Global and China Top Players Market's value chain where players are generating value. To get a complete picture, kindly read the entire report.
Insulin Biologics and Biosimilars Global and China Top Players has a wide range of applications, including
The Insulin Biologics and Biosimilars Global and China Top Players Market is expected to grow at a moderate CAGR during the forecast period of 2024 to 2029.
The convergence of various vital triggers, including a major slowdown in Western economies, and some critical points in globalization, leads to the transformation of business in the Insulin Biologics and Biosimilars Global and China Top Players Market across the extensive corporate landscape.
The Insulin Biologics and Biosimilars Global and China Top Players study focuses on shifting market dynamics, geopolitical and regulatory regulations, and key players' strategies to carefully analyze demand at risk across multiple industry categories.
